Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-02-14
2006-02-14
Krass, Frederick (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S302400
Reexamination Certificate
active
06998413
ABSTRACT:
Yungamycin A has been demonstrated to have unexpected in vivo anticancer activity. New compounds Yungamycin B and C are also disclosed, and have been demonstrated to be specific for DT-diaphorase, as well as to have in vivo anticancer activity.
REFERENCES:
patent: 5246955 (1993-09-01), Skibo et al.
Skibo et al, “Studies of Pyrrolo[1,2-a]benzimidazolequinone DT-Diaphorose Substrate Activity . . .”, J. Med. Chem., vol. 40, pp. 1327-1329 (1997).
Arizona Board of Regents acting for and on behalf of Arizona Sta
Craig, P.C. Fennemore
Krass Frederick
LandOfFree
Treatment of neoplasms with yujungamycins does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of neoplasms with yujungamycins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of neoplasms with yujungamycins will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3645670